Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

POTS brain fog targeted in new drug study

NCT ID NCT01988883

Knowledge-focused Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether a single dose of modafinil, a drug that promotes wakefulness, can improve concentration and mental clarity in people with Postural Tachycardia Syndrome (POTS). About 20 adults diagnosed with POTS will take the drug and then complete computer-based tests of attention and thinking. The goal is to better understand the 'brain fog' common in POTS and explore potential treatment options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

20 people

The number who actually took part.

Started

Oct 2014

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females of all races between the ages of 18 to 60 years * Diagnosed with POTS by the Vanderbilt Autonomic Dysfunction Center based on the following consensus criteria:(a) an increase in heart rate ≥ 30 beats per minute within 10 minutes of changing from the supine to standing position; (b) absence of orthostatic hypotension (defined as a decrease in systolic blood pressure ≥ 20 mmHg or diastolic blood pressure ≥ 10 mmHg upon standing); and (c) chronic symptoms (≥ 6 months) consistent with POTS that are worse with standing and are relieved by lying down * Able and willing to provide informed consent Exclusion Criteria: * Overt causes for POTS such as acute dehydration and bed rest deconditioning * Patients taking serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors * Known allergies or contraindications to study medications * Pregnancy or breast-feeding * Inability to give or withdraw informed consent * Other factors which in the investigator's opinion would prevent the subject from completing the study protocol such as poor compliance during previous studies * Asthma (due to the contraindication of propranolol for asthma patients)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postural tachycardia syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autonomic nervous system disorder cardiovascular disorder nervous system disorder Neurobehavioral Manifestations Neurologic Manifestations Orthostatic Intolerance postural orthostatic tachycardia syndrome primary dysautonomia Tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postural tachycardia syndrome

Contacts and locations

Locations

  • Vanderbilt University

    Nashville, Tennessee, 37211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.